The attorneys at Williams Cuker Berezofsky are reviewing claims of patients experiencing severe bleeding problems while using the drug Pradaxa.
According to the FDA, Pradaxa (dabigatran) is a blood-thinning medication used to reduce the risk of stroke and blood clots in patients with a specific condition called non-valvular atrial fibrillation (A-Fib), a heart rhythm problem that causes the heart to beat rapidly and irregularly.
Have you or someone close to you experience excessive bleeding that was difficult for doctors to stop, a stroke or other serious health problems while taking or after taking Pradaxa?
Williams Cuker Berezofsky attorneys are representing patients harmed by Pradaxa. Call for a no cost, no obligation consultation to learn your legal options, 215-557-0099 or fill out this inquiry form to learn more.
In 2014, the FDA issued a Drug Safety Communication: A study of patients found that risks were lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa compared to the drug warfarin. Warfarin was originally approved as the brand name Coumadin in 1954 and has been in wide use since that time.
Manufactured by Boehringer Ingelheim, Pradaxa has been under scrutiny since its approval in 2010.
The first official warnings of severe gastrointestinal bleeding that was very difficult to stop were issued by the FDA in 2012, with the followup communication mentioned above in 2014.